Zhejiang Kanying Import & Export Co. Ltd 86--17169758851 kanyingexport@gmail.com
131543-23-2 WIN 55212-2 Mesylate High Content 99% Purity

131543-23-2 WIN 55212-2 Mesylate High Content 99% Purity

  • High Light

    131543-23-2 WIN 55212-2 Mesylate

    ,

    High Content WIN 55212-2 Mesylate

    ,

    99% WIN 55212-2 Mesylate

  • Product Title
    WIN 55212-2 Mesylate
  • CAS No
    131543-23-2
  • PSA
    106.45000
  • Brand Name
    Kan Ying
  • Purity
    99%
  • Color
    White Powder
  • Storage
    Cool Dry Place
  • Shelf Life
    2 Years
  • Place of Origin
    India
  • Brand Name
    Kan Ying
  • Minimum Order Quantity
    1kg
  • Price
    To discuss
  • Packaging Details
    1kg-25kg
  • Delivery Time
    2
  • Payment Terms
    L/C, D/A, D/P, T/T, Western Union, MoneyGram,Dollars
  • Supply Ability
    200000

131543-23-2 WIN 55212-2 Mesylate High Content 99% Purity

131543-23-2 WIN 55212-2 Mesylate High Quality And High Content Factory Direct Sales From Stock

 

1. Product title: WIN 55212-2 Mesylate

 

2. Uses of Sildenafil Mesylate:
WIN 55,212-2 Mesylate is a potent cannabinoid receptor agonist with Ki values of 62.3 and 3.3 nM for human recombinant CB1 and CB2 receptors, respectively.

 

3. In vitro studies:

WIN 55,212-2 was 6 times more effective in CHO-CB2 cells than in CHO-CB1 cells. WIN 55,212-2 had no effect on arachidonic acid release in CHO-CB2 or control CHO cells. WIN 55,212-2 failed to stimulate an increase in intracellular Ca2+ up to 10 μM[1]. In primary cultures of rat cerebral cortical neurons, WIN 55,212-2 (0.01-100 nM) increased extracellular glutamate levels, showing a bell-shaped concentration-response curve. By replacing normal Krebs Ringer-bicarbonate buffer with low Ca2+ medium (0.2 mM) and IP(3) receptors, SR151716A (10 nM) completely counteracted the promoting effect of WIN 55,212-2 (1 nM). Antagonist xestospongin C (1 μM) [2]. WIN 55,212-2 evoked CGRP release from TG neurons in vitro in a concentration- and calcium-dependent manner (EC 50 = 26 μM). WIN 55,212-2-2 neither inhibited capsaicin-releasing CGRP release nor forskolin, isopropanol or prostaglandin E2-stimulated cAMP accumulation. WIN 55,212-2 significantly inhibited (EC50=1.7 μM) 50 mm K+-induced CGRP release by approximately 70%. The inhibitory effect of WIN 55,212-2 on 50 mm K+-evoked CGRP release is not reversed by antagonists of cannabinoid type 1 (CB1) receptors, but mimics the size and potency of its cannabinoid inactive enantiomer, WIN 55,212-2 (EC50 = 2.7 μM)-3 [3].

131543-23-2 WIN 55212-2 Mesylate High Content 99% Purity 0

4. In vivo studies:

In prefrontal cortex WIN 55,212-2 (0.1 and 1 mg/kg ip) increased dialysate glutamate levels in awake rats, while lower (0.01 mg/kg) and higher (2 mg/kg) doses were ineffective. In addition, the WIN 55,212-2 (0.1 mg/kg)-induced increase in dialysate glutamate levels was mediated by pretreatment with the selective CB(1) receptor antagonist SR141716A (0.1 mg/kg, ip) and low-dose local perfusion offset. -calcium Ringer solution (Ca2 + 0.2mM) [2]. WIN 55,212-2 (0.5, 1, 3, 5, 10 and 15 mg/kg, ip) did not alter seizure thresholds at low doses, whereas higher doses of the drug significantly increased thresholds in a dose-dependent manner. In the group pretreated with 20 mg/kg pioglitazone, an anticonvulsant effect of WIN 55,212-2 was observed at doses as high as 5 mg/kg and as low as 0.5 mg/kg [4].

 

131543-23-2 WIN 55212-2 Mesylate High Content 99% Purity 1